The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change

Archives of Medical Research

Volumn 40, Issue 6, 2009, Pages 478-485

  Franco, Eduardo L ^a   Mahmud, Salaheddin M ^a,c   Tota, Joseph ^a   Ferenczy, Alex ^a,b   Coutlée, François ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cervical cancer; Human papillomavirus; Pap cytology; Screening; Vaccination

Indexed keywords

SILGARD; UNCLASSIFIED DRUG; VIRUS DNA; WART VIRUS VACCINE;

CANCER SCREENING; CLINICAL TRIAL; CYTOLOGY; DIAGNOSTIC VALUE; HUMAN; PAPANICOLAOU TEST; PERSISTENT VIRUS INFECTION; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VACCINATION; WART VIRUS;

EID: 70350064318     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2009.06.003     Document Type: Review

References (42)

1. IARC Working Group. Human papillomaviruses. IARC Monographs on the evaluation of carcinogenic risks to humans Vol. 64 (1995), International Agency for Research on Cancer, Lyon
2. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
3. Franco E.L., Rohan T.E., and Villa L.L. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 91 (1999) 506-511
4. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 367 (2006) 1247-1255
5. Villa L.L., Costa R.L., Petta C.A., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
6. Ault K.A., and Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
7. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
8. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 (2003) 781-789
9. Goldie S.J., Kohli M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004) 604-615
10. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 (2004) 1915-1923
11. Rogoza R.M., Ferko N., Bentley J., et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 26 (2008) F46-F58
12. Hildesheim A., Herrero R., Wacholder S., et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298 (2007) 743-753
13. Munoz N., Bosch F.X., Castellsague X., et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
14. Benard V.B., Eheman C.R., Lawson H.W., et al. Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001. Obstet Gynecol 103 (2004) 564-571
15. Sangwa-Lugoma G., Mahmud S., Nasr S.H., et al. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer 119 (2006) 1389-1395
16. Saslow D., Runowicz C.D., Solomon D., et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 52 (2002) 342-362
17. Clifford G.M., Rana R.K., Franceschi S., et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 (2005) 1157-1164
18. Franco E.L., Cuzick J., Hildesheim A., et al. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 (2006) S171-S177
19. Franco E.L., and Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26S (2008) A16-A23
20. Nanda K., McCrory D.C., Myers E.R., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 132 (2000) 810-819
21. Cuzick J., Clavel C., Petry K.U., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 (2006) 1095-1105
22. Mayrand M.H., Duarte-Franco E., Rodrigues I., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
23. Arbyn M., Bergeron C., Klinkhamer P., et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 111 (2008) 167-177
24. Miller A.B., Nazeer S., Fonn S., et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer 86 (2000) 440-447
25. Franco E.L., Tsu V., Herrero R., et al. Integration of human papillomavirus vaccination and cervical cancer screening in Latin America and the Caribbean. Vaccine 26 (2008) L88-L95
26. Spitzer M. Screening and management of women and girls with human papillomavirus infection. Gynecol Oncol 107 (2007) S14-S18
27. Wright Jr. T.C., Massad L.S., Dunton C.J., et al. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
28. Arbyn M., Buntinx F., Van Ranst M., et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96 (2004) 280-293
29. Sankaranarayanan R., Nene B.M., Dinshaw K.A., et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer 116 (2005) 617-623
30. Kotaniemi-Talonen L., Nieminen P., Anttila A., et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 93 (2005) 862-867
31. Kitchener H.C., Almonte M., Wheeler P., et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95 (2006) 56-61
32. Naucler P., Ryd W., Törnberg S., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357 (2007) 1589-1597
33. Bulkmans N., Berkhof J., Rozendaal L., et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370 (2007) 1764-1772
34. Ronco G., Giorgi-Rossi P., Carozzi F., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100 (2008) 492-501
35. Franco E.L. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J Natl Cancer Inst Monogr 31 (2003) 89-96
36. IARC Working Group. Cervix cancer screening. IARC Handbooks of Cancer Prevention, International Agency for Research on Cancer, World Health Organization (2005), IARC Press
37. Arbyn M., Sasieni P., Meijer C.J., et al. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 (2006) S78-S89
38. Wright Jr. T.C., Schiffman M., Solomon D., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 103 (2004) 304-309
39. Dillner J., Rebolj M., Birembaut P., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening:joint European cohort study. BMJ 337 (2008) :a1754. doi:10.1136/bmj.a1754
40. Depuydt C.E., Arbyn M., Benoy I.H., et al. Quality control for normal liquid based cytology: rescreening, high risk HPV targeted reviewing and/or high risk HPV detection?. J Cell Mol Med (2008 Jun 9) [Epub ahead of print]
41. Sasieni P., and Cuzick J. Could HPV testing become the sole primary cervical screening test?. J Med Screen 9 (2002) 49-51
42. Cuzick J., Mayrand M.H., Ronco G., et al. Chapter 10: New dimensions in cervical cancer screening. Vaccine 24 (2006) S90-S97